Cardiovascular agents

Why sprinting to change clinical practice guidelines on blood pressure treatment is premature

Caution is required when the media reports on high profile medical studies.…

Pharmacy intervention improves adherence to cardiovascular medication

Patients had significantly better adherence scores following community pharmacy intervention measures.…

Concerns raised about trial supporting top selling anticoagulant drug

The validity of the data produced by a pivotal trial to gain approval for the direct oral anticoagulant, rivaroxaban (Xarelto), from the US and European regulators, has been called into question by an investigation.…

Evidence mounts on benefits of lowering threshold for use of antihypertensives

All patients at high risk of heart disease including those with normal blood pressure should be considered eligible for blood pressure-lowering drugs, new research suggests.…

FDA approves selexipag for pulmonary arterial hypertension

The US drugs safety regulator has approved selexipag to treat adults with pulmonary arterial hypertension, a chronic, progressive lung disease that causes high pressure in the arteries that connect the heart to the lungs.…

Novel anti-platelet therapy shows promise in first human trials

New anti-platelet drug set for phase II study after success in patients with coronary heart disease.…

New heart failure drug extends survival by up to two years

A re-analysis of trial data reveals that the highly effective new drug sacubitril-valsartan could extend life by two years compared with enalapril for cardiovascular patients.…

Negative media coverage about statins may lead patients to stop therapy early

Negative press coverage about statins has been linked to patients deciding to stop taking their statin therapy too early, researchers warn.…

Lowering blood pressure targets cuts cardiovascular disease deaths

Study shows treatment using lower blood pressure targets reduces chance of cardiovascular death by 43%.…

Intensive lowering of blood pressure cuts heart attacks and strokes, review says

Intensive blood pressure reduction is more beneficial for patients than less intensive BP reduction, concludes a review published in The Lancet.…